Kagocel, pills 12mg, 10pcs

Composition

>

of 1 tab. contains:

Active ingredients:

kagocel 12 MGYU

Auxiliary substances:

potato starch-10 mg,

calcium stearate-0.65 mg,

ludipress (direct pressed lactose with the composition: lactose monohydrate, povidone (collidone 30),

crospovidone (collidone CL)) – until a tablet weighing 100 mg

is obtained Pharmacological action

The main mechanism of action of Kagocel® is the ability to induce interferon production. Kagocel® causes the formation of so-called late interferons in the human body, which are a mixture of alpha-and beta-interferons with high antiviral activity. Kagocel ® induces interferon production in almost all cell populations involved in the body’s antiviral response: T and B lymphocytes, macrophages, granulocytes, fibroblasts, and endothelial cells. When a single dose of Kagocel® is taken orally, the interferon titer in the blood serum reaches its maximum values after 48 hours. The interferon response of the body to the use of Kagocel® is characterized by prolonged (up to 4-5 days) circulation of interferons in the bloodstream. The dynamics of interferon accumulation in the intestine during oral use of Kagocel® does not coincide with the dynamics of titers of circulating interferons. In the blood serum, interferon production reaches high values only 48 hours after taking Kagocel®, while in the intestine, the maximum interferon production is noted after 4 hours. Kagocel®, when administered in therapeutic doses, is non-toxic, does not accumulate in the body. The drug does not have mutagenic and teratogenic properties, is not carcinogenic and does not have an embryotoxic effect. The greatest effectiveness in the treatment of Kagocel® is achieved when it is prescribed no later than the 4th day after the onset of acute infection. For preventive purposes, the drug can be used at any time, including immediately after contact with the causative agent of infection. Pharmacokinetics Within 24 hours after use, Kagocel® accumulates mainly in the liver, to a lesser extent in the lungs, thymus, spleen, kidneys, and lymph nodes. Low concentrations are found in adipose tissue, heart, muscles, testicles, brain, and blood plasma. The low content of Kagocel® in the brain is explained by the high molecular weight of the drug, which makes it difficult for it to penetrate the blood-brain barrier. In the blood plasma, the drug is mainly in bound form. With repeated daily use of Kagocel®, the volume of distribution varies widely in all organs studied. Accumulation of the drug in the spleen and lymph nodes is particularly pronounced. When taken orally, about 20% of the administered dose of the drug enters the general bloodstream. The absorbed drug circulates in the blood, mainly in the form associated with macromolecules: with lipids-47%, with proteins-37%. The unbound portion of the drug is about 16%. The drug is mainly excreted through the intestines: 7 days after use,88% of the administered dose is excreted from the body, including 90% – through the intestines and 10% – by the kidneys. The drug was not detected in the exhaled air.

Indications

Kagocel® is used in adults as a preventive and therapeutic agent for influenza and other acute respiratory viral infections( ARVI), as well as as a treatment for herpes.

Kagocel® is used in children aged from 6 years as a preventive measure for influenza and other acute respiratory infections.

Kagocel® is used in children aged from 3 years as a treatment for influenza and other acute respiratory infections.

Contraindications

Increased individual sensitivity, pregnancy, age up to 3 years, lactase deficiency, lactose intolerance, glucose-galactose malabsorption.

Side effects

Allergic reactions may occur.

Interaction

Kagocel® is well combined with other antiviral drugs, immunomodulators and antibiotics (additive effect).

How to take, course of use and dosage

For oral use.

For the treatment of influenza and acute respiratory viral infections, adults are prescribed 2 Kagocel tablets 3 times a day in the first two days, and one tablet 3 times a day in the next two days. Total for the course – 18 tablets, duration of the course-4 days.

Prevention of influenza and ARVI in adults is carried out in 7-day cycles: two days – 2 tablets 1 time a day,5 days break, then repeat the cycle. The duration of the preventive course is from one week to several months.

For the treatment of herpes in adults,2 tablets are prescribed 3 times a day for 5 days. A total of 30 tablets per course, the duration of the course is 5 days.

For the treatment of influenza and acute respiratory viral infections, children aged 3 to 6 years are prescribed 1 tablet of Kagocel 2 times a day in the first two days, and one tablet 1 time a day in the next two days. Total for the course – 6 tablets, duration of the course-4 days.

For the treatment of influenza and acute respiratory viral infections, children aged from 6 years are prescribed 1 tablet 3 times a day in the first two days, and one tablet 2 times a day in the next two days. Total for the course – 10 tablets, duration of the course-4 days.

Prevention of influenza and acute respiratory viral infections in children aged 6 years and older is carried out in 7-day cycles: two days – 1 tablet of Kagocel 1 time a day,5 days break, then repeat the cycle. The duration of the preventive course is from one week to several months.

Overdose

In case of accidental overdose, it is recommended to prescribe a heavy drink, induce vomiting.

Special instructions

To achieve a therapeutic effect, Kagocel® should be started no later than the fourth day after the onset of the disease.

Form of production

Tablets, round, biconvex, cream-colored, interspersed.

Storage conditions

Store in a dry place, protected from light, at a temperature not exceeding 25 °C

Shelf life

2 years

Dosage form

Tablets